Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy: A southwest oncology group study

Between 1974 and 1977, 652 patients with non‐Hodgkin's lymphoma without prior chemotherapy were randomized to 1 of 3 combination chemotherapy programs designed to induce complete remission (CR): COP‐bleomycin (180 patients), CHOP‐bleomycin (232 patients) or CHOP plus immunotherapy with Bacillus Calmette Guerin (BCG) (240 patients). With mature follow‐up, the major effect of BCG immunotherapy was observed in patients with large cell lymphomas (diffuse or nodular “histiocytic”) and not in other common lymphoma subtypes. CR rate for 65 patients with large cell lymphoma treated with CHOP‐BCG was 68% compared to 48% in 61 patients treated with CHOP‐bleomycin (P = 0.02) (two‐tailed test) or 44% for 45 patients treated with COP‐bleomycin (P = 0.02). CR duration for both CHOP‐based regimens was similar and superior to that produced by COP‐bleomycin (P = 0.03). Survival of patients with large cell lymphoma treated with CHOP‐BCG was better than that observed with CHOP‐bleomycin (P = 0.02) or COP‐Bleomycin (P = 0.002). Although the explanation for the favorable effect of BCG remains unclear, further clinical trials to evaluate the combination of chemotherapy and other “biologic response modifiers” is warranted for patients with lymphoma.

[1]  D. Goldgaber,et al.  New hemorrhagic fever with renal syndrome-related virus in rodents in the United States. , 1982, Lancet.

[2]  S. Jones,et al.  Immunocompetence and malignant lymphoma: Immunologic status before therapy , 1981, Cancer.

[3]  L. Norton,et al.  Nodular histiocytic lymphoma: an aggressive nodular lymphoma with potential for prolonged disease-free survival. , 1980, Blood.

[4]  C. Bloomfield,et al.  Clinical utility of lymphocyte surface markers combined with the Lukes-Collins histologic classification in adult lymphoma. , 1979, The New England journal of medicine.

[5]  C. Coltman,et al.  Superiority of adriamycin‐containing combination chemotherapy in the treatment of diffuse lymphoma. A southwest oncology group study , 1979, Cancer.

[6]  K. Sikora,et al.  Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. , 1978, The New England journal of medicine.

[7]  D. Morton,et al.  Clinical trials of immunotherapy. Present status , 1978, Cancer.

[8]  C. Coltman,et al.  Histopathologic review of lymphoma cases from the southwest oncology group , 1977, Cancer.

[9]  B. Ramot,et al.  Effect of levamisole on E-rosette-forming cells in vivo and in vitro in Hodgkin's disease. , 1976, The New England journal of medicine.

[10]  E. Gehan,et al.  Chemoimmunotherapy of adult acute leukaemia. Prolongation of remission in myeloblastic leukaemia with B.C.G. , 1974, Lancet.

[11]  J. Sokal,et al.  Delay in progression of malignant lymphoma after BCG vaccination. , 1974, The New England journal of medicine.

[12]  L. Einhorn,et al.  Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin. , 1974, The New England journal of medicine.

[13]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[14]  G. Mathé,et al.  Active immunotherapy for acute lymphoblastic leukaemia. , 1969, Lancet.

[15]  E. Gehan.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. , 1965, Biometrika.

[16]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[17]  Henry Rappaport,et al.  Follicular lymphoma. A re‐evaluation of its position in the scheme of malignant lymphoma based on a survey of 253 cases , 1956 .

[18]  S. Jones,et al.  Effects of BCG on peripheral blood counts and drug tolerance of patients with non-Hodgkin lymphoma receiving combination chemotherapy. , 1978, Medical and pediatric oncology.